Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L5 pseudogenes are processed genomic sequences that resemble the protein-coding RPL5 gene but lack the capacity to encode a functional protein due to mutations or truncations[2][4][6]. The original RPL5 gene encodes a component of the large (60S) ribosomal subunit, critical for ribosome assembly and protein synthesis, and is associated with specific human diseases when mutated (e.g., Diamond-Blackfan anemia)[1][3][5]. However, pseudogenes such as "ENSG00000268105" do not contribute to ribosome function or serve as molecules targeted by drugs, are not enzymes, receptors, ion channels, or signaling proteins, and thus are not considered therapeutic targets.
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L5 pseudogene.